Daily Summary
The U.S. biotech market was rattled after the FDA’s top vaccine official was forced to step down, causing significant stock drops among major drugmakers as concerns grew over changes in vaccine policy under new leadership. Meanwhile, the CDC rescheduled its vaccine advisory meeting to April following recent leadership changes, and the EPA announced plans to dismantle its scientific research program, potentially cutting over 1,000 jobs and sparking warnings about reduced environmental protections.
EPA Plans Major Cuts to Research Office, Threatening Over 1,000 Jobs
The EPA plans to dismantle its scientific research office as part of a 65% budget cut, a move that could lead to more than 1,000 job losses and is being criticized for compromising public health and environmental protections.
US Vaccine Advisory Meeting Rescheduled for April
The CDC’s vaccine advisory meeting has been rescheduled for April 15-16, 2025, after a delay to allow for public comment following HHS Secretary Robert F. Kennedy Jr.'s confirmation. The updated agenda includes a measles update with additional topics to be announced.
Pharma Stocks Sink After FDA Vaccine Regulator Is Forced Out
Peter Marks, the FDA’s leading vaccine official, was forced to resign effective April 5 amid a government overhaul led by Health Secretary Robert F. Kennedy Jr. This move has led to a significant drop in pharma stocks, including those of Moderna and Pfizer.